CD19 and diffuse large B-cell lymphoma: In a single-center, phase 2a study, Tisagenlecleucel (a CD19 targeted CAR-T cell therapy developed by Norvartis) was tested in adult relapsed or refractory DLBCL who were ineligible for or had disease progression after autologous HSCT.